Reviews Urokinase Injection


No reviews yet.

Kinlytic Drug Description
Kinlytic™
(urokinase) for Injection
DRUG DESCRIPTION



What are the possible side effects of urokinase (Abbokinase, Kinlytic)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers at once if you have a serious side effect such as:

easy bruising or bleeding (nosebleeds, bleeding gums, bleeding from a wound, incision, catheter, or needle injection );
bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy...
Read All Potential Side Effects for Kinlytic »




Kinlytic™ (urokinase for injection) is a thrombolytic agent obtained
from human neonatal kidney cells grown in tissue culture. The principal active
ingredient of Kinlytic™ is the low molecular weight form of urokinase,
and consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a
B chain of 30,400 daltons. Kinlytic™ is supplied as a sterile lyophilized
white powder containing 250,000 international units urokinase per vial, mannitol
(25 mg/vial), Albumin (Human) (250 mg/vial), and sodium chloride (50 mg/vial).
Following reconstitution with 5 mL of Sterile Water for Injection, USP, Kinlytic™
is a clear, slightly straw-colored solution; each mL contains 50,000 international
units of urokinase activity, 0.5% mannitol, 5% Albumin (Human), and 1% sodium
chloride (pH range 6.0 to 7.5).
Thin translucent filaments may occasionally occur in reconstituted Kinlytic™
vials (see DOSAGE AND ADMINISTRATION).
Kinlytic™ is for intravenous infusion only.
Kinlytic™ is produced from human neonatal kidney cells (see WARNINGS).
No fetal tissue is used in the production of Kinlytic™. Kidney donations
are obtained exclusively in the United States from neonates (birth to 28 days)
for whom death has not been attributed to infectious causes and that have exhibited
no evidence of an infectious disease based in part, on an examination of the
maternal and neonatal donor medical records. The maternal and neonatal donor
screening process also identifies specific risk factors for known infectious
diseases and includes testing of sera for HBV, HCV, HIV-1, HIV-2, HTLV-I, HTLV-II,
CMV, and EBV. Donors with sera testing positive or associated with other risk
factors are excluded. During the manufacturing process, cells are tested at
multiple stages for the presence of viruses using in vitro and in
vivo tests that are capable of detecting a wide range of viruses. Cells
are also screened for HPV using a DNA detection-based test and for reovirus
using a polymerase chain reaction-based test. The manufacturing process used
for this product has been validated in laboratory studies to inactivate and/or
remove a diverse panel of spiked model enveloped and nonenveloped viruses, and
includes purification steps and a heat treatment step (10 hours at 60°C
in 2% sodium chloride). A single vial of Kinlytic™ contains urokinase
produced using cells derived from one or two donors.Last reviewed on RxList: 8/7/2008




Kinlytic Drug Description
Kinlytic™
(urokinase) for Injection
DRUG DESCRIPTION



What are the possible side effects of urokinase (Abbokinase, Kinlytic)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers at once if you have a serious side effect such as:

easy bruising or bleeding (nosebleeds, bleeding gums, bleeding from a wound, incision, catheter, or needle injection );
bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy...
Read All Potential Side Effects for Kinlytic »




Kinlytic™ (urokinase for injection) is a thrombolytic agent obtained
from human neonatal kidney cells grown in tissue culture. The principal active
ingredient of Kinlytic™ is the low molecular weight form of urokinase,
and consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a
B chain of 30,400 daltons. Kinlytic™ is supplied as a sterile lyophilized
white powder containing 250,000 international units urokinase per vial, mannitol
(25 mg/vial), Albumin (Human) (250 mg/vial), and sodium chloride (50 mg/vial).
Following reconstitution with 5 mL of Sterile Water for Injection, USP, Kinlytic™
is a clear, slightly straw-colored solution; each mL contains 50,000 international
units of urokinase activity, 0.5% mannitol, 5% Albumin (Human), and 1% sodium
chloride (pH range 6.0 to 7.5).
Thin translucent filaments may occasionally occur in reconstituted Kinlytic™
vials (see DOSAGE AND ADMINISTRATION).
Kinlytic™ is for intravenous infusion only.
Kinlytic™ is produced from human neonatal kidney cells (see WARNINGS).
No fetal tissue is used in the production of Kinlytic™. Kidney donations
are obtained exclusively in the United States from neonates (birth to 28 days)
for whom death has not been attributed to infectious causes and that have exhibited
no evidence of an infectious disease based in part, on an examination of the
maternal and neonatal donor medical records. The maternal and neonatal donor
screening process also identifies specific risk factors for known infectious
diseases and includes testing of sera for HBV, HCV, HIV-1, HIV-2, HTLV-I, HTLV-II,
CMV, and EBV. Donors with sera testing positive or associated with other risk
factors are excluded. During the manufacturing process, cells are tested at
multiple stages for the presence of viruses using in vitro and in
vivo tests that are capable of detecting a wide range of viruses. Cells
are also screened for HPV using a DNA detection-based test and for reovirus
using a polymerase chain reaction-based test. The manufacturing process used
for this product has been validated in laboratory studies to inactivate and/or
remove a diverse panel of spiked model enveloped and nonenveloped viruses, and
includes purification steps and a heat treatment step (10 hours at 60°C
in 2% sodium chloride). A single vial of Kinlytic™ contains urokinase
produced using cells derived from one or two donors.Last reviewed on RxList: 8/7/2008




Kinlytic Drug Description
Kinlytic™
(urokinase) for Injection
DRUG DESCRIPTION



What are the possible side effects of urokinase (Abbokinase, Kinlytic)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers at once if you have a serious side effect such as:

easy bruising or bleeding (nosebleeds, bleeding gums, bleeding from a wound, incision, catheter, or needle injection );
bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy...
Read All Potential Side Effects for Kinlytic »




Kinlytic™ (urokinase for injection) is a thrombolytic agent obtained
from human neonatal kidney cells grown in tissue culture. The principal active
ingredient of Kinlytic™ is the low molecular weight form of urokinase,
and consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a
B chain of 30,400 daltons. Kinlytic™ is supplied as a sterile lyophilized
white powder containing 250,000 international units urokinase per vial, mannitol
(25 mg/vial), Albumin (Human) (250 mg/vial), and sodium chloride (50 mg/vial).
Following reconstitution with 5 mL of Sterile Water for Injection, USP, Kinlytic™
is a clear, slightly straw-colored solution; each mL contains 50,000 international
units of urokinase activity, 0.5% mannitol, 5% Albumin (Human), and 1% sodium
chloride (pH range 6.0 to 7.5).
Thin translucent filaments may occasionally occur in reconstituted Kinlytic™
vials (see DOSAGE AND ADMINISTRATION).
Kinlytic™ is for intravenous infusion only.
Kinlytic™ is produced from human neonatal kidney cells (see WARNINGS).
No fetal tissue is used in the production of Kinlytic™. Kidney donations
are obtained exclusively in the United States from neonates (birth to 28 days)
for whom death has not been attributed to infectious causes and that have exhibited
no evidence of an infectious disease based in part, on an examination of the
maternal and neonatal donor medical records. The maternal and neonatal donor
screening process also identifies specific risk factors for known infectious
diseases and includes testing of sera for HBV, HCV, HIV-1, HIV-2, HTLV-I, HTLV-II,
CMV, and EBV. Donors with sera testing positive or associated with other risk
factors are excluded. During the manufacturing process, cells are tested at
multiple stages for the presence of viruses using in vitro and in
vivo tests that are capable of detecting a wide range of viruses. Cells
are also screened for HPV using a DNA detection-based test and for reovirus
using a polymerase chain reaction-based test. The manufacturing process used
for this product has been validated in laboratory studies to inactivate and/or
remove a diverse panel of spiked model enveloped and nonenveloped viruses, and
includes purification steps and a heat treatment step (10 hours at 60°C
in 2% sodium chloride). A single vial of Kinlytic™ contains urokinase
produced using cells derived from one or two donors.Last reviewed on RxList: 8/7/2008




Kinlytic Drug Description
Kinlytic™
(urokinase) for Injection
DRUG DESCRIPTION



What are the possible side effects of urokinase (Abbokinase, Kinlytic)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers at once if you have a serious side effect such as:

easy bruising or bleeding (nosebleeds, bleeding gums, bleeding from a wound, incision, catheter, or needle injection );
bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy...
Read All Potential Side Effects for Kinlytic »




Kinlytic™ (urokinase for injection) is a thrombolytic agent obtained
from human neonatal kidney cells grown in tissue culture. The principal active
ingredient of Kinlytic™ is the low molecular weight form of urokinase,
and consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a
B chain of 30,400 daltons. Kinlytic™ is supplied as a sterile lyophilized
white powder containing 250,000 international units urokinase per vial, mannitol
(25 mg/vial), Albumin (Human) (250 mg/vial), and sodium chloride (50 mg/vial).
Following reconstitution with 5 mL of Sterile Water for Injection, USP, Kinlytic™
is a clear, slightly straw-colored solution; each mL contains 50,000 international
units of urokinase activity, 0.5% mannitol, 5% Albumin (Human), and 1% sodium
chloride (pH range 6.0 to 7.5).
Thin translucent filaments may occasionally occur in reconstituted Kinlytic™
vials (see DOSAGE AND ADMINISTRATION).
Kinlytic™ is for intravenous infusion only.
Kinlytic™ is produced from human neonatal kidney cells (see WARNINGS).
No fetal tissue is used in the production of Kinlytic™. Kidney donations
are obtained exclusively in the United States from neonates (birth to 28 days)
for whom death has not been attributed to infectious causes and that have exhibited
no evidence of an infectious disease based in part, on an examination of the
maternal and neonatal donor medical records. The maternal and neonatal donor
screening process also identifies specific risk factors for known infectious
diseases and includes testing of sera for HBV, HCV, HIV-1, HIV-2, HTLV-I, HTLV-II,
CMV, and EBV. Donors with sera testing positive or associated with other risk
factors are excluded. During the manufacturing process, cells are tested at
multiple stages for the presence of viruses using in vitro and in
vivo tests that are capable of detecting a wide range of viruses. Cells
are also screened for HPV using a DNA detection-based test and for reovirus
using a polymerase chain reaction-based test. The manufacturing process used
for this product has been validated in laboratory studies to inactivate and/or
remove a diverse panel of spiked model enveloped and nonenveloped viruses, and
includes purification steps and a heat treatment step (10 hours at 60°C
in 2% sodium chloride). A single vial of Kinlytic™ contains urokinase
produced using cells derived from one or two donors.Last reviewed on RxList: 8/7/2008




Kinlytic Drug Description
Kinlytic™
(urokinase) for Injection
DRUG DESCRIPTION



What are the possible side effects of urokinase (Abbokinase, Kinlytic)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers at once if you have a serious side effect such as:

easy bruising or bleeding (nosebleeds, bleeding gums, bleeding from a wound, incision, catheter, or needle injection );
bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds;
chest pain or heavy...
Read All Potential Side Effects for Kinlytic »




Kinlytic™ (urokinase for injection) is a thrombolytic agent obtained
from human neonatal kidney cells grown in tissue culture. The principal active
ingredient of Kinlytic™ is the low molecular weight form of urokinase,
and consists of an A chain of 2,000 daltons linked by a sulfhydryl bond to a
B chain of 30,400 daltons. Kinlytic™ is supplied as a sterile lyophilized
white powder containing 250,000 international units urokinase per vial, mannitol
(25 mg/vial), Albumin (Human) (250 mg/vial), and sodium chloride (50 mg/vial).
Following reconstitution with 5 mL of Sterile Water for Injection, USP, Kinlytic™
is a clear, slightly straw-colored solution; each mL contains 50,000 international
units of urokinase activity, 0.5% mannitol, 5% Albumin (Human), and 1% sodium
chloride (pH range 6.0 to 7.5).
Thin translucent filaments may occasionally occur in reconstituted Kinlytic™
vials (see DOSAGE AND ADMINISTRATION).
Kinlytic™ is for intravenous infusion only.
Kinlytic™ is produced from human neonatal kidney cells (see WARNINGS).
No fetal tissue is used in the production of Kinlytic™. Kidney donations
are obtained exclusively in the United States from neonates (birth to 28 days)
for whom death has not been attributed to infectious causes and that have exhibited
no evidence of an infectious disease based in part, on an examination of the
maternal and neonatal donor medical records. The maternal and neonatal donor
screening process also identifies specific risk factors for known infectious
diseases and includes testing of sera for HBV, HCV, HIV-1, HIV-2, HTLV-I, HTLV-II,
CMV, and EBV. Donors with sera testing positive or associated with other risk
factors are excluded. During the manufacturing process, cells are tested at
multiple stages for the presence of viruses using in vitro and in
vivo tests that are capable of detecting a wide range of viruses. Cells
are also screened for HPV using a DNA detection-based test and for reovirus
using a polymerase chain reaction-based test. The manufacturing process used
for this product has been validated in laboratory studies to inactivate and/or
remove a diverse panel of spiked model enveloped and nonenveloped viruses, and
includes purification steps and a heat treatment step (10 hours at 60°C
in 2% sodium chloride). A single vial of Kinlytic™ contains urokinase
produced using cells derived from one or two donors.Last reviewed on RxList: 8/7/2008





Other reviews about Urokinase Injection on wordpress

Intracerebral clot clean-up
  by tomography
Stroke is the leading cause of life-threatening neurologic disease and the third leading cause of death in the United States, with an incidence of 500,000 cases per year. […]


Cerebral sinus thrombosis
  by Yasser Metwally
The author:Professor Yasser Metwally http://yassermetwally.com INTRODUCTION Background: Thrombosis of the venous channels in the brain is an uncommon cause of cerebral infarction relative to arterial disease but is an important consideration […]


Contoh Soal-soal NCLEX Test bag-1
  by adimasmw
NCLEX test adalah semacam test kompetensi bagi perawat yang ingin mendapatkan lisensi profesional keperawatan. NCLEX test ini dikeluarkan oleh NCSBN (semacam PPNI-nya amrik), jadi kalo kita berminat untuk […]


3. Allvarliga risker
  by alternativmedicin
Halsryggsmanipulation och art√§rskador Det finns m√•nga rapporter om allvarliga skador efter nackmanipulation utf√∂rd av kiropraktorer och andra. Detta f√∂rnekas vanligen av kiropraktorerna sj√§lva, b√•de i Sverige och andra l√§nder. […]


Renal and Retroperitoneal Abscesses
  by urologysurgery
Renal and retroperitoneal abscesses are uncommon clinical entities that often pose a significant diagnostic challenge. Nonspecific signs and symptoms frequently lead to a delay in diagnosis and treatment. […]


PHARMACOLOGY MNEMONICS
  by doctorstube
Pulmonary infiltrations inducing drugs "Go BAN Me!":GoldBleomycin/ Busulphan/ BCNUAmiodarone/ Acyclovir/ AzathioprineNitrofurantoinMelphalan/ Methotrexate/ Methysergide MPTP: mechanism, effect MPTP:Mitochondrial Parkinson's-Type Poison.¬∑ A mitochondrial poison that elicits a Parkinson's-type effect. Antimuscarinics: […]


Nursing Board Exam Questions l Nursing Practice Test
  by ryanrey
1. A patient tells you that her urine is starting to look discolored. If you believe this change is due to medication, which of the following patient's medication […]


Cardiovascular Risks from H1N1 Swine Flu Vaccines
  by canadiansforhealthfreedom
Cardiovascular Risks from Swine Flu Vaccines Overstimulation of the immune system may trigger acute heart disease and sudden deaths in the increasing number of people with atherosclerosis; this hidden […]


Cerebral Infarction Therapy
  by stroketreatment
Cerebral infarction is not as dangerous as¬†cerebral hemorrhage, but it should treat as soon as possible. As for most patients are in old age and weak, with several […]


, by which time the te
  by yqipbxqcsbsrx
It was a glistening, whiteandblue day. One was into the Socialist Party; the other was into the Republican Party. We must make sure of the newcomers. But the […]



Other reviews about Urokinase Injection on web:

Consumer information about the medication UROKINASE - INJECTION (Abbokinase), includes side effects, drug interactions, recommended dosages, and storage information. Read more ... UROKINASE - INJECTION (Abbokinase) side effects, medical uses, and ...


Urokinase Injection. 18 November 2009. Products Affected - Description Bulletin


Urokinase (Injection) ... You should not receive this medicine if you have had an allergic reaction to urokinase, or ... Kelsey-Seybold Clinic - Welcome


Urokinase, Injection yoor-oh-KYN-ace What are other names for this medicine? Type of medicine: thrombolytic Generic and brand names: urokinase, injection; Abbokinase CRS Topic


Urokinase (Injection) ... You should not receive this medicine if you have had an allergic reaction to urokinase, or ... Health Library


A method for preparing a stable urokinase injection by the liophilization of urokinase which comprises liophilizing an aqueous solution containing urokinase, human Method for preparing urokinase injection - US 4244943


Urokinase (ure-oh-KYE-nase) Treats blood clots of the lung (pulmonary embolism). Allina Hospitals & Clinics - Urokinase (Injection)


Learn all about Urokinase (Injection). Urokinase (ure-oh-KYE-nase) Treats blood clots of the lung (pulmonary embolism). Urokinase (Injection) - Drug Information


Urokinase (Injection): Urokinase (ure-oh-KYE-nase)Treats blood clots of the lung (pulmonary embolism). Urokinase (Injection)


Learn about the prescription medication Kinlytic (Urokinase Injection), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Kinlytic (Urokinase Injection) Drug Information: Uses, Side ...





Featured Reviews

Reviews B12

B12 Drug Description B12 (vitamin b12) Capsules DRUG DESCRIPTION A Highly Potent Oral Antianemia Preparation Each capsule contains: Special Liver-Stomach Concentrate (containing Intrinsic Factor) 240mg Vitamin...
Read More  |  Review This
Reviews Wellbutrin XL

Wellbutrin XL Drug Description WELLBUTRIN XL® (bupropion hydrochloride) Extended-Release Tablets WARNING Suicidality and Antidepressant Drugs Use in Treating Psychiatric Disorders: Antidepressants increased the risk compared...
Read More  |  Review This
Reviews Diphtheria and Tetanus Toxoids

Diphtheria and Tetanus Drug Description Diphtheria and Tetanus Toxoids Adsorbed USP (For Pediatric Use) Caution: Federal (USA) law prohibits dispensing without prescription. DRUG DESCRIPTION What are the possible side effects...
Read More  |  Review This
Reviews Periochip

Periochip Drug Description PerioChip® (chlorhexidine gluconate) 2.5 mg DRUG DESCRIPTION PerioChip® (chlorhexidine gluconate) is a small, orange-brown, rectangular chip (rounded at one end) for insertion into periodontal pockets....
Read More  |  Review This
Reviews Necon

Necon Drug Description Necon® 1/35 (norethindrone and ethinyl estradiol) Tablets USP Necon® 0.5/35 (norethindrone and ethinyl estradiol) Tablets USP Necon® 10/11 (norethindrone and ethinyl estradiol) Tablets USP Necon®...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....